Showing 3841-3850 of 9150 results for "".
- Suneva to Market and Distribute Neauvia's Plasma IQ in North Americahttps://practicaldermatology.com/news/suneva-to-market-and-distribute-neauvias-plasma-iq-in-north-america/2460534/Suneva Medical, Inc., will market and distribute Neauvia Plasma IQ throughout North America as part of a new partnership. The first Class 2 FDA-cleared plasma energy device, Plasma IQ delivers focused, controlled plasma energy to create microinjuries on the skin, renewing
- SENTÉ Names Adelle Walker as Chief Marketing Officerhttps://practicaldermatology.com/news/sente-names-adelle-walker-as-chief-marketing-officer/2460080/SENTÉ® has appointed Adelle Walker Chief Marketing Officer. As Chief Marketing Officer (CMO), she will take an executive leadership role in defining pipeline strategy along with internal and external portfolio planning. Her commercialization leadership will span across all fa
- ISHRS Awareness Campaign Takes on Black Market Hair Restoration Clinicshttps://practicaldermatology.com/news/ishrs-awareness-campaign-takes-on-black-market-hair-restoration-clinics/2460016/The International Society of Hair Restoration Surgery (ISHRS) is launching a new public awareness campaign to help patients recognize “black market pirate” hair restoration clinics and misleading advertising claims. Social media engagement will be the cornerstone of the new
- Encore Dermatology Acquires Marketing Rights to Promius Pharma Brandshttps://practicaldermatology.com/news/encore-dermatology-acquires-marketing-rights-to-promius-pharma-brands-1/2459989/Encore Dermatology is purchasing the US rights to market Sernivo® (betamethasone dipropionate) Spray, 0.05% and is being assigned the rights to market and distribute Promiseb® Topical Cream and Trianex® 0.05% (Triamcinolone Acetonide Ointment, USP) from Dr. Reddy’
- Almirall's Seysara Set to Shake Up US Acne Markethttps://practicaldermatology.com/news/almiralls-seysara-set-to-shake-up-us-acne-market/2457557/The US Food and Drug Administration’s approval of Almirall’s Seysara (sarecycline) for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients ages nine and older is set to shake up the currently stagnant acne market due to its ease of adminis
- Ekwa Marketing Launches Affiliate Program, Offers Residual Income Opportunity for Medical Associationshttps://practicaldermatology.com/news/ewa-marketing-launches-affiliate-program-offers-residual-income-opportunity-for-medical-associations/2457622/Ekwa Marketing has launched its unique Ekwa Affiliate Program. Medical associations can simply place an online link to Ekwa’s innovative digital marketing products for doctors on their website and social media networks, and start receiving a passive i
- DermTech Receives Health Canada Approval to Market PLA and Non-invasive Biopsy Kithttps://practicaldermatology.com/news/dermtech-receives-health-canada-approval-to-market-pla-and-non-invasive-biopsy-kit/2457937/DermTech, Inc's licensee, DermTech Canada Inc., has received approval to market DermTech’s Pigmented Lesions Assay (PLA) and non-invasive biopsy kit for the detection of melanoma in Canada. DermTech Canada will market and sell the PLA, and samples will be processed at DermTech’s c
- Save the Dates: eRelevance Launches National Marketing Education Tour for Aesthetic Healthcare Practiceshttps://practicaldermatology.com/news/erelevance-launches-national-marketing-education-tour-for-aesthetic-healthcare-practices/2457983/eRelevance Corporation announced the expansion of its popular marketing education workshops to more cities nationwide. The workshops help aesthetic healthcare providers understand the significant opportunity in marketing to their existing patient
- Biofrontera Appoints Jeffrey Holm as VP of Marketinghttps://practicaldermatology.com/news/biofrontera-appoints-jeffrey-holm-as-vp-of-marketing/2458013/Biofrontera AG, which specializes in the treatment of sun-induced skin cancer, has appointmented Jeffrey Holm as Vice President of Marketing, to further strengthen its US commercialization activities.
- Aclaris Submits Marketing Authorization Application in Europe for A-101 40% for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-submits-marketing-authorization-application-in-europe-for-a-101-40-for-seborrheic-keratosis/2458100/Aclaris Therapeutics, Inc. has submitted a Marketing Authorization Application (MAA) with the Medicines Product Agency (MPA) in Sweden for its product candidate A-101 40% Topical Solution for the treatment of seborrheic keratosis. The MPA will act as the reference member state in this decentraliz